Treatment outcome of 100 patients with hepatoblastoma based on a new risk stratification
10.3760/cma.j.cn112152-20190603-00347
- VernacularTitle:100例肝母细胞瘤基于新危险分层的治疗结果分析
- Author:
Zijun ZHEN
1
;
Juncheng LIU
;
Li ZHOU
;
Zhe XU
;
Zhichong ZHANG
;
Feifei SUN
;
Suying LU
;
Jia ZHU
;
Juan WANG
;
Junting HUANG
;
Xiaofei SUN
Author Information
1. 中山大学肿瘤防治中心儿童肿瘤科 华南肿瘤学国家重点实验室，广州 510060
- Keywords:
Hepatoblastoma;
Risk stratification;
Comprehensive treatment;
Survival rate
- From:
Chinese Journal of Oncology
2021;43(2):228-232
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To provide the risk stratification method of hepatoblastoma (HB) suitable for implementation in China and explore the new treatment method for high-risk HB patients.Methods:A total of 100 cases of children and adolescents under 18 years old with newly diagnosed HB in Sun Yat-sen University Cancer Center and Sun Yat-sen University First Affiliated Hospital from September 2014 to September 2018 were included. According to the clinical stage, AFP level, pathological subtype and other factors, patients were stratified into four groups: extremely low-, low-, intermediate- and high-risk. The patients at very low risk were treated with surgery only and followed-up. The patients at very low risk were treated with C5V(Cisplatin+ 5-Fluroracil+ Vincristine) regimen for 4 courses. The patients at intermediate risk were treated with C5VD(Cisplatin+ 5-Fluroracil+ Vincristine+ Doxorubicin)regimen before and after surgery for 6-8 courses. The patients at high risk were treated with C5VD and IIV (ifoshamide+ irinotecan+ vincristine) alternately before and after surgery for 8 courses.Results:One hundred patients were stratified into extremely low-risk, low-risk, medium-risk and high-risk groups for 2, 10, 51 and 37 cases, respectively. Eighty three cases had evaluable lesions before chemotherapy. Among them, 65 patients achieved partial remission, stable disease and progressive disease were observed in 10, and 8 cases, respectively, with a response rate of 78.3%. During a median follow-up of 20 months, 30 patients experienced tumor relapse or progression, and 27 of them died. The 2-years progression-free survival (PFS) and overall survival (OS) rates were 69.2% and 72.0%, respectively. The 2-years PFS rates of patients with extremely low risk, low risk, medium risk and high risk were 100%, 88.9%, 75.3% and 43.2%, respectively. The 2-years OS rates were 100%, 100%, 81.0% and 44.8%, respectively.Conclusions:The novel HB risk classification is simple and feasible. With active comprehensive treatment, patients at extremely low-, low- and medium-risk have excellent outcomes. The survival rate of high-risk HB patients remains to be improved, and new treatment strategies need to be explored.
